Conatus Pharmaceuticals to Highlight Anticipated Clinical Data Readouts at Upcoming Investor Conferences
“We intend to use the upcoming conferences to provide context for our four planned data readouts, the first being the announcement of top-line results from our POLT-HCV-SVR trial in the second quarter,” said Dr. Mento. “This randomized, placebo-controlled Phase 2b trial is evaluating two years of treatment with emricasan, our first-in-class pan-caspase inhibitor, in post-orthotopic liver transplant (POLT) recipients with liver fibrosis or cirrhosis post-transplant as a result of recurrent hepatitis C virus (HCV) infection who have successfully achieved a sustained viral response (SVR) following HCV antiviral therapy.”
“In collaboration with
- At the
Roth Capital Partners30th Annual Conference ( March 11-14in Laguna Niguel, CA), Dr. Mento will participate in two panel discussions on NASH cirrhosis on Monday, March 12, as part of the integrated Spring NASH Bash. Dr. Mento and Dr. Marshall will meet with investment professionals and will provide an overview and update presentation beginning at 1:30 p.m. ETon Monday, March 12.
- At the
H.C. Wainwright2nd Annual NASH Investor Conference( March 19in New York), Dr. Marshall will present a NASH-focused presentation beginning at 3:40 p.m.
- At the
Oppenheimer Healthcare Conference( March 20-21in New York), Dr. Mento and Dr. Marshall will meet with investment professionals and will provide an overview and update presentation beginning at 10:20 a.m. ETon Wednesday, March 21. An audio webcast and copy of the Oppenheimer conference presentation will be available in the Investors section of the company’s website at www.conatuspharma.com.
Conatus is a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease. In collaboration with
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward looking statements, including statements regarding: the timelines to announce results from the four ongoing clinical trials; expansion of the company’s development pipeline; the sufficiency of current financial resources to maintain operations through 2019, as well as to fund initial pipeline expansion activities; and caspase inhibitors' potential to interrupt the progression of a variety of diseases. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including those risks described in the company’s prior press releases and in the periodic reports it files with the
Source: Conatus Pharmaceuticals Inc.